==== Front Ann Saudi MedAnn Saudi MedAnnals of Saudi Medicine0256-49470975-4466King Faisal Specialist Hospital and Research Centre 2356300710.5144/0256-4947.2013.169asm-2-169Systematic ReviewEfficacy of telbivudine on interruption of hepatitis B virus vertical transmission: a meta-analysis Liu Min-Hui Sheng Yun-Jian Liu Jun-Ying Hu Huai-Dong Zhang Qiong-Fang Ren Hong From theaDepartment of Infectious Diseases, Institute of Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, ChinaCorrespondence: Hong Ren, MD, Department of Infectious Diseases, Institute of Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University. 74#Linjiang Road, Chongqing 400010 China, renhong0531@vip.sina.comMar-Apr 2013 33 2 169 175 Copyright © 2013, Annals of Saudi Medicine2013This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.BACKGROUND AND OBJECTIVES Hepatitis B virus (HBV) infection is one of the most common infections in the world. Vertical transmission is the main reason for the continued endemic infection rates, at least in Asia. This study aimed to investigate the efficacy of telbivudine on mother-to-child transmission (MTCT) interruption. METHODS Studies up to April 2012 were collected by searching Pubmed, EMBASE, the Cochrane Library, EBM Review, WangFang Database and China National Knowledge Infrastructure. Serum hepatitis B surface antigen (HBsAg) and HBV DNA in newborns and infants, maternal HBV DNA negative conversion and alanine transaminase (ALT) normalization and adverse events were analyzed. RESULTS Seven clinical trials involving 644 pregnant women were included in this meta-analysis. Telbivudine resulted in lower HBsAg and HBV DNA seroprevalence in newborns and infants. When maternal viral load prior to delivery was higher than 103 copies/mL, HBsAg or HBV DNA positivity had no statistical difference. CONCLUSIONS Telbivudine treatment has efficacy and safety on MTCT interruption during late pregnancy. In addition, we demonstrated benefit of telbivudine for mothers in terms of HBV DNA negative conversion and ALT normalization. Telbivudine treatment at the end of pregnancy should be considered in women with high viral load. ==== Body Hepatitis B is one of the most common infectious diseases in the world. Of the 2 billion individuals infected by HBV, over 350 million are chronically infected,1 with chronic infection manifested by persistence of the virus and HBsAg in serum and production of viral antigens and HBV DNA in the liver. Cirrhosis, liver failure, or hepatocellular carcinoma (HCC) develop in 15% to 40% of individuals with chronic HBV infection,2 which are responsible for 1 million deaths per year.3 In southeast Asia, in the east or in Pacific regions, 30% to 50% of chronic infections in children are of vertical etiology linked to a high viral load in mothers. Presence of hepatitis B e antigen (HBeAg) in the mother’s serum is associated with greater infectivity: The risk of perinatal HBV infection among infants born to HBV-infected mothers ranges from 10% to 40% in HBeAg-negative mothers to 70% to 90% in HBeAg-positive mothers.4 Although highly effective in preventing MTCT, standard passive-active immunoprophylaxis with hepatitis B immunoglobulin (HBIG) and the hepatitis B vaccine may have a failure rate as high as 10% to 15%.5 History of threatened preterm labor, HBV in villous capillary endothelial cells, transplacental leakage of HBeAg-positive maternal blood, exposure to cervical secretions and maternal blood during labor and delivery, and specific allelic mutations in maternal HBV all may contribute to increased risk of MTCT.6–8 Studies7,9,10 show that the maternal HBV DNA level significantly affected the protective efficacy rate of passive- active immunoprophylaxis. The transition point in maternal viral load at which transmission rates begin to rise dramatically is approximately 106 to 108 copies/mL.10–12 Thus, it might be an effective way to reduce the rate of HBV infection in infants by decreasing maternal HBV DNA level with antiviral therapy. In women with high viral loads, antiviral treatment in the last trimester of pregnancy should be considered to reduce the risk of in-utero transmission.13,14 Five drugs are now FDA-approved for the treatment of HBV (interferon, lamivudine, adefovir, entecavir, and peginterferon alpha-2a) and divided into five categories (A, B, C, D, and X) for use in pregnancy. Currently there are no FDA category A anti-HBV medications. Lamivudine in category C (animal reproduction studies have shown an adverse effect on the fetus, there are no adequate and well-controlled studies in humans, and the benefits from the use of the drug in pregnant women may be acceptable despite its potential risks) - it is safe and well tolerated in HIV-infected pregnancy15– 18 and may also provide additional protection in pregnant women with high-level viremia according to a meta-analysis.19 Nevertheless, lamivudine resistant mutants emerge at a high rate of approximately 15% to 30% per year of therapy.20 Even an HBV DNA mutation in a newborn due to lamivudine therapy during the last trimester of pregnancy in the mother has been reported.21 Tenofovir in category B (animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women) was demonstrated a potent inhibitor of HIV and HBV replication, including activity against lamivudine-resistant HBV22–27 and approved for CHB therapy by the US FDA in August 2008. Unfortunately, it has not been approved yet or is still undergoing phase III trials in many countries including China. Telbivudine in category B has greater antiviral and clinical efficacy than lamivudine in patients with chronic hepatitis B, and less primary treatment failure and resistance.28–33 Much less is known about the effecacy of telbivudine on preventing vertical transmission of HBV in pregnant patients. Recently, several studies34–37 showed controversial results in blocking MTCT of telbivudine. This study aimed at meta-analyzing the published drug-based randomized and non-randomized controlled studies designed to evaluate the effecacy of telbivudine on the interruption of HBV MTCT in pregnant patients with high HBV DNA levels. According to the data, we evaluated the safety of telbivudine in mothers and infants additionally. METHODS Literature research and data extraction We seached PubMed, EMBASE, the Cochrane Library, EBM Review, WangFang Database and China National Knowledge Infrastructure for relevant articles up to April 2012. The key words “telbivudine”, “hepatitis B”, “vertical transmission”, “perinatal transmission”, “intrauterine transmission”, “mother-to-child transmission”, and their synonyms and related terms, were used. Reference lists from qualitative topic reviews and published clinical trials were also searched. Data extraction was conducted independently by two investigators (Liu MH and Liu JY). Articles were examined to eliminate duplicate reports of the same trials. Inclusion and exclusion criteria A inclusive clinical trial had to fulfil the following criteria: a prospective randomized controlled or nonrandomized controlled study; telbivudine treatment for women infected by HBV in late pregnancy; maternal viral load higher than 106copies/mL at baseline; all infants given vaccine and HBIG within 12 hours of birth, vaccinated a second dose at weeks 4 and a final dose at week 24; serum parameters including HBsAg and HBV DNA as MTCT end-point. The most frequent reasons for exclusion were publication in an ineligible format including letters/abstracts or the results provided were not from original research including reviews/editorials; patients were co-infected with other hepatitis virus or human immunodeficiency virus; there was no control group; antiviral treatment began at the first or second trimester of gestation. Efficacy measures The primary end points of interruption of MTCT were indicated by serum HBsAg, HBeAg and HBV DNA of newborns or infants aged 6–12 months. Secondary end point was serum antibody to hepatitis B surface antigen (anti-HBs) of infants aged 6-12 months. The primary end point of maternal virological response and biochemical response were proportion of patients with undetectable HBV DNA and proportion of ALT nomalization, respectively. Statistical methods Outcomes were analyzed on an intention-to-treat basis. In this meta-analysis, the results were expressed as risk ratios (RRs) and 95% confidence intervals (CIs), and P<.01 was considered statistically significant. Heterogeneity between trials was evaluated by the Cochrane Q-test. In addition, the consistency of effects among trials was evaluated by I2. A P value <.10 or I2>50% was considered indicative of statistically significant heterogeneity. According to the absence of significant heterogeneity, we used a fixed-effect model to obtain quantitative, pooled, summary RRs. Publication bias was assessed by funnel plots which displayed the studies in a plot of effect size against sample size, which mapped the log standard error against the log RR of individual studies.38 Data analysis was conducted by using Review Manager software 5.0 (Cochrane Collaboration, Oxford, United Kingdom). RESULTS Search results and characteristics We identified 72 articles by electronic search and excluded 54 irrelevant citations after reading abstracts. The process of article selection is shown in Figure 1. Among the 18 potentially relevant studies, two without control groups were excluded. One was rejected because patients in treatment group were treated with a combination of telbivudine and HBIG while patients in the control group were given HBIG alone. One was excluded because only one patient was enrolled. Six duplicate studies and one article without adequate information were excluded. Finally, seven clinical trials36,37,39–43 involving 644 pregnant women infected by HBV fulfilled our inclusion criteria. Of these, two were acquired from PubMed (Pan et al, 2012; Han et al, 2011), and the others were from Wang Fang Database and China National Knowledge Infrastructure published in Chinese (Chen et al, 2011; Yao et al, 2011; Cao et al, 2011; Zhang et al, 2010; Zhang et al, 2009). Only one of the included trials was a randomized, controlled clinical trial (Zhang et al, 2009). The 644 patients with a HBV DNA baseline level higher than 106 copies/mL had no historical antiviral-therapy before pregnancy except for ten in one study (Pan et al, 2012). Telbivudine was given to 350 patients in treatment group at an oral dose of 600 mg once daily mainly starting at 28 weeks gestational age in late pregnancy. The other 294 patients were left untreated and served as the controls. One patient received treatment from 12 weeks because of abnomal liver function (Zhang et al, 2009). The characteristics of the included studies were summarized in Table 1, Table 2 and Table 3. Serum HBsAg and HBV DNA of newborns within 24h after birth The efficacy of telbivudine on blocking MTCT in newborns was assessed in six trials containing the data of HBsAg seroprevalence and evaluated in three trials providing HBV DNA seroprevalence. Analysis showed efficacy of telbivudine on interrupting vertical transmission. A fixed-effect model was used because of the absence of heterogeneity (chi-square=4.98, P=0.42, I2=0%). The overall estimate for RR of telbivudine group vs. control group was 0.37 [95% CI 0.24, 0.56] (P<.00001) in serum HBsAg positivity (Figure 2). It was 0.25 [95% CI 0.11, 0.59] (P=0.001) in serum HBV DNA positivity, heterogeneity analysis chisquare= 0.41, P=0.81, I2=0% (Figure 2). Serum HBsAg and HBV DNA of infants aged 6–12 months Six trials providing data of serum HBsAg positivity in infants were evaluated. We observed a significant reduce of HBsAg seroprevalence in the treatment groups. The summary RR was 0.09 [95% CI 0.03, 0.26] (P<.00001) (Figure 3). Q-test for heterogeneity chi-square=0.31, P=1.00, I2=0%. Only 4 trials compared serum HBV DNA positivity in infants. All these trials showed a significant effect among infants from treated group with a common RR of 0.08 [95% CI 0.02, 0.29] (P=.0001) in favor of treatment (Figure 3). Q-test for heterogeneity chi-square=0.24, P=0.97, I2=0%. Maternal HBV DNA negative conversion and alanine transaminase normalization Only three trials contained data of maternal HBV DNA negative conversion and two had data of ALT normalization prior to delivery. In comparison with no treatment, telbivudine therapy resulted in higher HBV DNA negative conversion rate and ALT normalization rate among mothers. The pooled RR was 37.68 [95% CI 7.45, 190.47] (P<.0001), and 1.46 [95% CI 1.18, 1.80] (P=.0006), respectively (Figure 4). Serum HBsAg of newborns and infants born to mothers with different viral loads To investgate the influence of maternal HBV DNA levels on vertical transmission, we made an analysis by dividing the studies into two subgroups according to maternal HBV DNA levels before delivery in treated groups. When maternal HBV DNA level was lower than 103 copies/mL after treatment, HBsAg seroprevalence in newborns was reduced in comparison to the control group. The summary RR was 0.33 [95% CI 0.20, 0.53] (P<.00001) (Figure 5). However, when maternal HBV DNA level was higher than 103 copies/ mL, HBsAg positivity in the two groups had no statistical difference [RR 0.7; 95% CI 0.26, 1.89] (P=.49) (Figure 5). Among infants born to mothers with a HBV DNA level lower than 103copies/mL, the RR of HBsAg prevalence was 0.07 [95% CI 0.02, 0.31] (P=.0003) (Figure 6). No statistical difference was observed in HBsAg prevalence of infants when mothers’ HBV DNA level was higher than 103copies/mL [RR 0.11; 95% CI 0.01, 0.87] (P=.04) (Figure 6). These demonstrated that high maternal viral loads prior to delivery after treatment implied small efficacy of telbivudine on blocking vertical transmission of HBV and also corresponded to the theory regarding high maternal viral load as a high risk of MTCT. Safety Three studies reported adverse events in mothers (Han et al, 2011; Yao et al, 2011; Zhang et al, 2010), two of which described adverse events as serum creatine kinase (CK) elevation (Yao et al, 2011; Zhang et al, 2010) and the other one considered the events dug-unrelated (Han et al, 2011). Two studies reported adverse events among infants. One reported serum CK elevation (Zhang et al., 2009). In the other one, pneumonia occurred in three infants from the treated group and one from the control group, but it was not clear whether the occurrence was drug-related (Pan et al, 2012). Incidence of adverse events among mothers had a significant difference with a Peto odds ratio of 3.35 [95% CI 1.66, 6.73] (P=.0007). Adverse events among newborns/infants did not differ significantly between telbivudine and untreated groups [Peto odds ratio 0.98; 95% CI 0.37, 2.61](P=.97). DISCUSSION Multiple clinical trials have confirmed that telbivudine showed significantly greater HBV DNA suppression with less primary treatment failure and resistance in general in patients with chronic hepatitis B. Telbivudine has been generally well tolerated, with a low adverse effect profile.44 Telbivudine treatment at the end of pregnancy should be considered in women with a very high viral load to diminish the risk of vertical transmission. However, it is still controversial because of lack of data and evidence of efficacy. This meta-analysis adds further support to the efficacy of telbivudine on interrupting MTCT. Our study showed significant efficacy of telbivudine on preventing vertical transmission indicated both by serum HBsAg and HBV DNA in newborns (RR was 0.37 and 0.09, respectively.) or infants (RR was 0.25 and 0.08, respectively.). Transmission rate indicated by serum HBsAg in telbivudine group was much lower than that in control group among infants (0.3%, 1/330 vs. 12.3%, 33/268). Similarly, it was 0.4% (1/271) and 12.0% (25/208) respectively indicated by serum HBV DNA. It was demonstrated that MTCT incidence would increase in newborns or infants if maternal HBV DNA level was higher than 103 copies/mL prior to delivery. Analysis of HBV DNA negative conversion and ALT normalization also confirmed the definite efficacy of telbivudine on mothers. Serum HBsAg, HBeAg, and HBV DNA in newborns or infants are frequently used as routine indicators of MTCT. Beasley et al45 recommended high titers of HBsAg within 24 hours after birth and becoming HBsAg carrier after passive-active immunoprophylaxis as two criteria for perinatal infection diagnosis. Thus, evaluating MTCT within 24 hours after birth seems not entirely reasonable because the efficacy of the serovaccination must be confirmed in all children by a serologic examination (HBsAg and anti-HBs) at some time after the last vaccination.46 Though detecting techniques for serum HBV DNA now available are much more sensitive than which for HBV markers,9,47 HBV DNA is probably undetectable in patient infected by HBV, especially HBV carriers. So HBV DNA used as indicator solely to estimate vertical transmission rate would lead an unreliable result. Therefore, combination of HBsAg and HBV DNA testing within 24 hours and 6 to 12 months after birth should be suggested. There are reports of symptomatic myopathy, peripheral neuropathy and cardiac arrhythmia in patients receiving telbivudine, as well as a significantly higher incidence of grade 3 to 4 serum CK elevations noted in telbivudine-treated compared to lamivudine-treated patients at 2 years (12.9% versus 4.1%).30,48,49 CK elevation was observed in three analyzed studies and normalization occurred after drug discontinuance. Other adverse events or birth defects were not recorded. The difference of adverse events among infants between treated and control groups was not significant. Additionally, hepatitis flares can occur after discontinuation of antiviral therapy. 50 There are few data about excretion of telbivudine into breast milk. For these reasons, close monitoring is necessary if patients are to receive telbivudine treatment during pregnancy. The 6-week postpartum visit should serve as an opportunity to establish referrals.51 This meta-analysis presents some potential limitations. Firstly, the majority of studies included were nonrandomized controlled trials and the only randomized one had not described the method used to generate the allocation sequence. It was difficult to blind and allocate subjects randomly in consideration of informed consent before telbivudine therapy. Secondly, few studies and small samples were included in this meta-analysis. Thirdly, lack of some important information such as maternal HBeAg status and data of long-term postpartum follow up make it impossible to analyse further. Finally, publication bias existed in our study. Compared to positive studies, negative studies may be less likely to be published or more likely to take longer to be published, which can affect the validity of meta-analysis.52 In conclusion, telbivudine has a clear efficacy and safety on interrupting perinatal transmission of HBV in pregnant women with high viral load. It is also associated with a significantly greater proportion of patients achieving HBV DNA negative conversion and ALT normalization. Moreover, the efficacy of telbivudine on blocking MTCT can be implied by maternal HBV DNA level prior to delivery after treatment. Figure 1 Flow chart of literature selection. LDT: telbivudine, HBIG: hepatitis B immunoglobulin, RCT: randomized controlled trial, NRCT: non- randomized controlled trial. Figure 2 HBsAg and HBV DNA seroprevalence in newborns. Figure 3 HBsAg and HBV DNA seroprevalence in infants. Figure 4 Maternal HBV DNA negative conversion and ALT normalization prior to delivery. Figure 5 Influence of maternal HBV DNA level prior to delivery on HBsAg seroprevalence among newborns. Figure 6 Influence of maternal HBV DNA level prior to delivery on HBsAg seroprevalence in infants. Table 1 Baseline characteristics of clinical trials. First author, year Study design Age of mother Group (n) Interventions on mothers Maternal HBV DNA level (lg copies/ml) (mean[SD]) Before intervention Before delivery Pan,39 2012 NRCT, P 20–40 arm1: 53 LDT 600mg od from week 12 to 30 8.08 (6.62–9.42) 2.68 (0.84) 20–40 arm2: 35 no treatment 8.08 (6.67–9.08) 7.64 (0.72) Han,36 2011 NRCT, P 20–40 arm1: 135 LDT 600mg od from week 20 to 32 8.10 (0.56) 2.44 (1.79) 20–40 arm2: 94 no treatment 7.98 (0.61) 7.28 (0.66) Chen,40 2011 NRCT, P NA arm1: 25 LDT 600mg od from week 28 >7.0 NA NA arm2: 25 no treatment >7.0 NA Yao,41 2011 NRCT, P 28.9 arm1: 28 LDT 600mg od from week 28 7.5 (0.6) 3.3 (1.6) arm2: 30 no treatment 7.5 (0.7) 7.5 (0.6) Cao,42 2011 NRCT, P NA arm1: 18 LDT 600mg od from week 28 7.78 (0.58) 3.87 (1.12) NA arm2: 20 no treatment 7.45 (0.46) 7.42 (0.53) Zhang,43 2010 NRCT, P 23–36 arm1: 60 LDT 600mg od from week 28 lg[(6.62±0.9)×106] lg[(0.49±0.54)×103] 24–37 arm2: 60 no treatment lg[(7.22±1.27)×106] lg[(7.46±1.06)×106] Zhang,37 2009 RCT, P NA arm1: 31 LDT 600mg od from week 28 7.38 (0.81) 4.08 (0.52) NA arm2: 30 no treatment 7.46 (0.45) 7.38 (0.57) NRCT: non- randomized controlled trial ; RCT: randomized controlled trial P: prospective; LDT: telbivudine; od: once daily; NA: data not available; SD: Standard Error Table 2 Outcomes of newborns/infants. First author, year Newborns within 24h Infants aged 6–12 month HBsAg + HbeAg + HBV DNA + HBsAg + HBeAg + HBV DNA + anti-HBs + Pan, 2012 NA NA NA 0/54 0/54 0/54 NA NA NA NA 3/35 3/35 3/35 NA Han, 2011 13/136 NA NA 0/132 NA 0/132 132/132 28/94 NA NA 7/88 NA 7/88 81/88 Chen, 2011 1/25 NA 0/25 0/25 NA 0/25 NA 5/25 NA 4/25 4/25 NA 4/25 NA Yao, 2011 1/28 NA NA 0/28 NA NA NA 5/30 NA NA 4/30 NA NA NA Cao, 2011 3/18 NA 0/18 NA NA NA NA 2/20 NA 1/20 NA NA NA NA Zhang, 2010 6/60 NA 5/60 1/60 NA 1/60 NA 18/60 NA 18/60 11/60 NA 11/60 NA Zhang, 2009 2/31 NA NA 0/31 NA NA NA 2/30 NA NA 4/30 NA NA NA NA: data not available. Table 3 Outcomes of mothers and adverse events. First author, year ALT normalization before delivery Maternal HBV DNA (−) before delivery Adverse events Mothers Infants Pan, 2012 46/53 1/53 0/53 3/54 21/35 0/53 0/35 1/35 Han, 2011 30/36 NA 12/135 0/136 21/37 NA 5/94 0/94 Chen, 2011 NA NA 0/25 0/25 NA NA 0/25 0/25 Yao, 2011 NA NA 3/20 0/20 NA NA 2/30 0/30 Cao, 2011 NA 1/18 NA 0/18 NA 0/20 NA 0/20 Zhang, 2010 NA 52/60 13/60 0/60 NA 0/60 0/60 0/60 Zhang, 2009 NA NA 0/31 8/31 NA NA 0/30 9/30 (−): HBV DNA undetectable; NA: data not available. ==== Refs REFERENCES 1 World Health Organization Hepatitis B. World Health Organization Fact Sheet No 2004 Available at: http://who.int/mediacentre/factsheets/fs204/en accessed June 5, 2005 2 Lok AS Chronic hepatitis B N Engl J Med 2002 346 1682 1683 12037146 3 De Franchis R Hadengue A Lau G Lavanchy D Lok A McIntyre N EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland: consensus statement (long version) J Hepatol 2003 39 Suppl 1 S3 S25 14708673 4 Alter MJ Epidemiology of hepatitis B in Europe and worldwide J Hepatol 2003 39 suppl 1 S64 69 14708680 5 Buchanan C Tran TT Management of chronic hepatitis B in pregnancy Clin Liver Dis 2010 8 14 3 495 504 20638027 6 Jonas M Hepatitis B and pregnancy: an underestimated issue Liver Int 2009 29 Suppl 1 133 139 7 Xu DZ Yan YP Choi BC Xu JQ Men K Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study J Med Virol 2002 67 1 20 26 11920813 8 Lin HH Lee TY Chen DS Sung JL Ohto H Etoh T Transplacental leakage of HBeAg-positive maternal blood as the most likely route in causing intra-uterine infection with hepatitis B virus J Pediatr 1987 111 877 881 3681555 9 Zhang SL Han XB Yue YF Relationship between HBV viremia level of pregnant women and intrauterine infection: neated PCR for detection of HBV DNA World J Gastroenterol 1998 4 61 63 11819234 10 del Canho R Grosheide PM Mazel JA Heijtink RA Hop WC Gerards LJ Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982–1992: protective efficacy and long-term immunogenicity Vaccine 1997 15 1624 1630 9364693 11 Yuan J Lin J Xu A Li H Hu B Chen J Antepartum immunoprophylaxis of three doses of hepatitis B immunoglobulin is not effective: a single-centre randomized study J Viral Hepat 2006 13 597 604 16907846 12 Li XM Shi MF Yang YB Shi ZJ Hou HY Shen HM Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection World J Gastroenterol 2004 10 3215 3217 15457579 13 Arfaoui D Fkih M Hafsa AE Kaabia N Azzouz M Service de gastroentérologie, et al. Hepatitis B and pregnancy Tunis Med 2010 88 6 383 389 20517846 14 Boland GJ Veldhuijzen IK Janssen HL van der Eijk AA Wouters MG Boot HJ Management and treatment of pregnant women with hepatitis B Ned Tijdschr Geneeskd 2009 153 A905 20051170 15 Johnson MA Moore KH Yuen GJ Bye A Pakes GE Clinical pharmacokinetics of lamivudine Clin Pharmacokinet 1999 36 1 41 66 16 Moodley J Moodley D Pillay K Coovadia H Saba J van Leeuwen R Pharmacokinetics and antiretroviral activity of lamividine alone or when co-administered with zidovudine in HIV-infected pregnant women and their offspring J Infect Dis 1998 178 5 1327 1333 9780252 17 Chaisilwattana P Chokephaibulkit K Chalermchockcharoenkit A Vanprapar N Sirimai K Chearskul S Short-course therapy with zidovudine plus lamivudine for prevention of mother-to-child transmission of human immunodeficiency virus type 1 in Thailand Clin Infect Dis 2002 35 11 1405 1413 12439805 18 Silverman NS Watts DH Hitti J Money DM Livingston E Axelrod J Initial multicenter experience with double nucleoside therapy for human immunodeficiency virus infection during pregnancy Infect Dis Obstet Gynecol 1998 6 6 237 243 9972484 19 Han L Zhang HW Xie JX Zhang Q Wang HY Cao GW A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus World J Gastroenterol 2011 14 17 38 4321 4333 22090789 20 Leung N Lamivudine for chronic hepatitis B Expert Rev Anti Infect Ther 2004 4 2 2 173 180 15482184 21 Kazim SN Wakil SM Khan LA Hasnain SE Sarin SK Vertical transmission of hepatitis B virus despite maternal lamivudine therapy Lancet 2002 4 27 359 9316 1488 1489 11988251 22 Dore GJ Cooper DA Pozniak AL DeJesus E Zhong L Miller MD Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naïve and -experienced patients coinfected with HIV-1 and hepatitis B virus J Infect Dis 2004 189 7 1185 1192 15031786 23 Benhamou Y Fleury H Trimoulet P Pellegrin I Urbinelli R Katlama C Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients Hepatology 2006 43 548 555 16496322 24 Lok AS McMahon BJ Chronic hepatitis B Hepatology 2007 45 507 539 17256718 25 Matthews GV Avihingsanon A Lewin SR Amin J Rerknimitr R Petcharapirat P A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand Hepatology 2008 48 1062 1069 18697216 26 Marcellin P Heathcote EJ Buti M Gane E de Man RA Krastev Z Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N Engl J Med 2008 359 2442 2455 19052126 27 Hammer SM Eron JJ Jr Reiss P Schooley RT Thompson MA Walmsley S Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel JAMA 2008 300 555 570 18677028 28 Lai CL Leung N Teo EK Tong M Wong F Hann HW A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B Gastroenterology 2005 8 129 2 528 536 16083710 29 Lai CL Gane E Hsu CW Thongsawat S Wang YM Chen YG Two-year results from the globle trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LDT) vs. lamivudine Hepatology 2006 44 Suppl 1 222A 30 Lai CL Gane E Liaw YF Hsu CW Thongsawat S Wang Y Telbivudine versus lamivudine in patients with chronic hepatitis B N Engl J Med 2007 357 25 2576 2588 18094378 31 Zeuzem S Buti M Gane EJ Liaw Y Di Bisceglie AM Heathcote E Baseline parameters predict both early virologic response and longer term outcomes for telbivudine-treated patients with chronic hepatitis B (The Globe Study) Hepatology 2007 46 4 Suppl 1 681A 32 Gane E Lai CL Liaw YE Thongsawat S Wang Y Chen Y Phase III comparison of telbivudine vs lamivudine in HbeAg-positive patients with chronic hepatitis B: efficacy,safety,and predictors of response at 1 year J Hepatol 2006 44 Suppl 2 S183 S184 33 Hou J Yin YK Xu D Tan D Niu J Zhou X Telbivudine Versus Lamivudine in Chinese Patients with Chronic Hepatitis B: Results at 1 Year of a Randomized, Double-Blind Trial Hepatology 2008 47 2 447 54 18080339 34 Peters MG Special Populations with Hepatitis B Virus Infection Hepatology 2009 49 5 Suppl S146 55 19399810 35 Giles ML Visvanathan K Lewin SR Sasadeusz J Chronic hepatitis B infection and pregnancy Obstet Gynecol Surv 2012 67 1 37 44 22278077 36 Han GR Cao MK Zhao W Jiang HX Wang CM Bai SF A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection J Hepatol 2011 55 6 1215 1221 21703206 37 Zhang LJ Wang L Blocking intrauterine infection by telbivudine in pregnant chronic hepatitis B patients Chin J Hepatol 2009 17 8 561 563 38 Sterne JA Egger M Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis J Clin Epidemiol 2001 54 1046 1055 11576817 39 Pan CQ Han GR Jiang HX Zhao W Cao MK Wang CM Telbivudine Prevents Vertical Transmission from HBeAg-Positive Women with Chronic Hepatitis B Clin Gastroenterol Hepatol 2012 2 14 Epub ahead of print 40 Chen XQ Yao ZC Wu LP Chen MC Zhang YP Wu Y Clinical study on telbivudine in preventing mother-to-infant HBV transmission during the late pregnancy J Clini Hepatol 2011 27 12 1282 1284 41 Yao ZC Chen MC Liao YP Wu Y Li LY Feng J The efficacy and safety of telbivudine in blocking intrauterine hepatitis B viral transmission J Clini Hepatol 2011 4 4 259 261 42 Cao MK Han GR Jiang HX Sun M Wang CM Effect of telbivudine treatment on placenta HBV infection pregnant women with HBeAg+ HBV DNA high titer Jiangsu Med J 2011 37 4 419 421 43 Zhang YF Hu YH Efficacy and safety of telbivudine in preventing mother-to-infant HBV transmission ADRJ 2010 12 3 157 159 44 Kim JW Park SH Louie SG Telbivudine: A Novel Nucleoside Analog for Chronic Hepatitis B Ann Pharmacother 2006 40 3 472 478 16507625 45 Beasley RP Hwang LY Lee GC Lan CC Roan CH Huang FY Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine Lancet 1983 2 1099 1102 6138642 46 Bacq Y Hepatitis B and pregnancy Gastroenterol Clin Biol 2008 32 1 Pt 2 S12 19 18662605 47 Wang JS Chen H Zhu QR Transformation of hepatitis B serologic markers in babies born to hepatitis B surface antigen positive mothers World J Gastroenterol 2005 11 3582 3585 15962380 48 Zhang XS Jin R Zhang SB Tao ML Clinical features of adverse reactions associated with telbivudine World J Gastroenterol 2008 14 14 22 3549 3553 18567085 49 Liaw YF Gane E Leung N Zeuzem S Wang Y Lai CL 2-year GLOBE Trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B Gastroenterology 2009 136 486 495 19027013 50 Keeffe EB Dieterich DT Han SH Jacobson IM Martin P A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update Clin Gastroenterol Hepatol 2008 6 12 1315 1341 quiz: 1286 18845489 51 Gambarin-Gelwan M Hepatitis B in pregnancy Clin Liver Dis 2007 11 4 945 63 17981236 52 Thornton A Lee P Publication bias in meta-analysis: its causes and consequences J Clin Epidemiol 2000 53 2 207 216 10729693